Company profile
Viking Therapeutics, Inc.
Pipeline6 assets
- VK2735 (Subcutaneous)VK2735 / Dual GLP-1/GIP receptor agonist / Peptide / Metabolic DisordersObesity
- VK2735 (Oral)VK2735 / Dual GLP-1/GIP receptor agonist / Peptide / Metabolic DisordersObesity
- VK2809VK2809 / Thyroid hormone receptor beta (TRβ) agonist / Small molecule / Metabolic DisordersNASHFibrosisNAFLD
- VK0214VK0214 / Thyroid hormone receptor beta (TRβ) agonist / Small molecule / Rare DiseasesX-linked adrenoleukodystrophy (X-ALD)
- Amylin Agonist (DACRAs)Dual amylin and calcitonin receptor agonist (DACRA) / Agonist / Metabolic DisordersObesityMetabolic disorders
- VK5211VK5211 / Selective androgen receptor modulator (SARM) / Small molecule / Musculoskeletal DisordersHip fracture recoveryMuscle and bone disorders
Latest news16 items
All newsViking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
Trial Results • Phase 2Topline results Tue, Sep 22, 2026, 8:00 AM ET
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Enrollment • Phase 3Enrollment milestone Tue, Jun 30, 2026
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Trial Start • Phase 1Trial initiation Wed, Jun 24, 2026
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
Presentation / Abstract • Phase 2ECO poster presentation Tue, May 12, 2026
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
Presentation / Abstract • Phase 2